文献速递淋巴瘤

固定疗程维奈克拉联合奥妥珠单抗治疗初治慢性淋巴细胞白血病后维奈克拉巩固治疗(HOVON 139/GiVe):多中心、开放标签、随机、平行组、2期试验的主要终点分析

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2022-01-01

在荷兰25家医院开展的开放标签随机2期试验中,初治且不适合氟达拉滨治疗的慢性淋巴细胞白血病患者先接受固定疗程维奈克拉联合奥妥珠单抗治疗,随后按微小残留病状态随机接受12周期维奈克拉巩固或仅微小残留病阳性时巩固;两组达到主要终点(骨髓微小残留病不可测且无进展)的比例分别为50%和53%,巩固治疗未阻止微小残留病应答丢失及后续复发风险。

要点

  • 固定疗程维奈克拉联合奥妥珠单抗后,12周期维奈克拉巩固组与微小残留病导向巩固组主要终点达成率分别为50%和53%。
  • 巩固组任何不良事件(2-4级,主要为感染)发生率为69%,微小残留病导向巩固组为37%。
  • 作者认为12周期维奈克拉巩固延长已知副作用持续时间,且不能防止微小残留病应答丢失和后续疾病复发风险。

核心结论

  • 12周期维奈克拉巩固治疗延长已知副作用持续时间,且不能防止微小残留病应答丢失和后续疾病复发风险。

研究设计与样本

  • 开放标签、随机、平行组、2期试验(HOVON 139/GiVe),在荷兰25家医院开展。
  • 纳入70例初治慢性淋巴细胞白血病患者,年龄18岁及以上,ECOG体能状态0-2,不适合氟拉达滨为基础的治疗。
  • 所有患者先接受2个减瘤周期静脉奥妥珠单抗,随后接受固定疗程12周期维奈克拉联合奥妥珠单抗。
  • 67例接受固定疗程治疗,62例按外周血微小残留病状态1:1随机分配至12周期维奈克拉巩固组(n=32)或微小残留病导向维奈克拉巩固组(n=30,其中1例随机时微小残留病阳性)。
  • 主要终点为意向治疗人群中巩固治疗结束(或相应时间点)后3个月骨髓微小残留病不可测且无进展疾病。

主要发现

  • 中位随访35.2个月(IQR 31.5-41.3)。
  • 巩固组32例中16例(50% [95% CI 32-68])达到主要终点,微小残留病导向巩固组30例中16例(53% [34-72])达到主要终点。
  • 巩固组32例中22例(69%)发生任何不良事件(2-4级,主要为感染),微小残留病导向巩固组30例中11例(37%)发生任何不良事件。
  • 最常见的3级或以上不良事件为感染(巩固组32例中2例[6%],微小残留病导向巩固组30例中1例[3%])和中性粒细胞减少(巩固组32例中2例[6%],微小残留病导向巩固组30例中2例[7%])。
  • 无治疗相关死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated patients with chronic lymphocytic leukaemia who were unfit for fludarabine-based treatment, and whether this could be guided by minimal residual disease status. METHODS: We conducted an open-label, randomised, parallel-group, phase 2 trial (HOVON 139/GiVe) at 25 hospitals in the Netherlands. Eligible patients were aged 18 years or older with previously untreated chronic lymphocytic leukaemia, had an ECOG performance status of 0-2, and were unfit for fludarabine-based treatment. All patients received two debulking cycles of intravenous obinutuzumab (100 mg on day 1, 900 mg on day 2, and 1000 mg on days 8, 15, and day 1 of cycle two), followed by fixed-duration venetoclax plus obinutuzumab for 12 cycles (six cycles of intravenous obinutuzumab 1000 mg on day 1 and 12 during 28-day cycles of oral venetoclax, starting with a 5-week ramp-up and then 400 mg once daily until completion of cycle 12). Patients were then randomly assigned (1:1) by minimal residual disease status in peripheral blood, to receive either 12 cycles of venetoclax consolidation irrespective of minimal residual disease or venetoclax consolidation only if minimal residual disease was detected at randomisation. The primary endpoint was undetectable minimal residual disease in bone marrow and no progressive disease 3 months after end of consolidation treatment (or corresponding timepoint) by intention-to-treat. Safety was assessed in all patients who received at least one dose of any study drug. This is the primary endpoint analysis of this trial, which is ongoing and is registered with EudraCT (2015-004985-27). FINDINGS: Between Oct 28, 2016, and May 31, 2018, 70 patients were enrolled, of whom 67 (47 [70%] men and 20 [30%] women) received fixed-duration treatment and 62 were randomly assigned to receive 12 cycles of venetoclax consolidation (n=32) or minimal residual disease-guided venetoclax consolidation (n=30; one of whom was minimal residual disease positive at randomisation). Median follow-up was 35·2 months (IQR 31·5-41·3). 16 (50% [95% CI 32-68]) of 32 patients in the consolidation group and 16 (53% [34-72]) of 30 in the minimal residual disease-guided consolidation group met the primary endpoint of undetectable minimal residual disease in bone marrow and no progressive disease. 22 (69%) of 32 patients in the venetoclax consolidation group and 11 (37%) of 30 in the minimal residual disease-guided consolidation group had any adverse event (grade 2-4; mainly infections). The most common grade 3 or worse adverse events were infection (two [6%] of 32 patients in the consolidation group and one [3%] of 30 in the minimal residual disease-guided consolidation group) and neutropenia (two [6%] and two [7%]). There were no treatment-related deaths. INTERPRETATION: Consolidation with venetoclax 12-cycle treatment increases the duration of known side-effects and does not prevent the loss of minimal residual disease response and subsequent risk of disease relapse. FUNDING: F Hoffmann-La Roche.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kersting S, Dubois J, Nasserinejad K, et al. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematol. 2022. PMID: 35240075. doi:10.1016/S2352-3026(22)00034-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。